Vyant Bio, Inc.·4

Apr 1, 9:32 PM ET

Horobin Joanna 4

4 · Vyant Bio, Inc. · Filed Apr 1, 2021

Insider Transaction Report

Form 4
Period: 2021-03-30
Transactions
  • Award

    Stock option (right to buy)

    2021-03-30+13,01513,015 total
    Exercise: $4.61From: 2021-03-30Exp: 2031-03-30Common Stock (13,015 underlying)
  • Other

    Stock option (right to buy)

    2021-03-30+5,0685,068 total
    Exercise: $1.56From: 2021-03-30Exp: 2030-12-01Common Stock (5,068 underlying)
Footnotes (1)
  • [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. These options are fully vested.

Documents

1 file
  • 4
    ownership.xmlPrimary